MedTrace Logo

A Study of the Effectiveness and Safety of SP2086 to Treat Type 2 Diabetes

NCT01969357 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2013-10-25

No results posted yet for this study

Summary

SP2086 is a new dipeptidy1 peptidase(DPP)-4 inhibitors. This study aims to explore the effective dose range of SP2086 in Patients with type 2 diabetes.

Conditions

Interventions

DRUG

Placebo

Tablets(n=4),once daily for 84 days

DRUG

50 mg SP2086

Tablets(n=1),50mg strength+tablets(n=3) 0 mg once daily for 84 days

DRUG

100 mg SP2086

Tablets(n=1),100 mg strength+tablets(n=3) once 0 mg daily for 84 days

DRUG

200 mg SP2086

Tablets(n=2),100 mg strength+tablets(n=2) 0mg once daily for 84 days

DRUG

100 mg Sitagliptin

Tablets(n=1),100 mg strength+tablets(n=3),0 mg strength once daily for 84 days

Sponsors & Collaborators

  • Jiangsu HengRui Medicine Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Changyu Pan, M.D. · Chinese PLA General Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-06-30
Primary Completion
2012-04-30
Completion
2012-06-30

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01969357 on ClinicalTrials.gov